Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery
“Our study is the first to assess how the Afirma GSC performs in
real-world clinical practice,” said
In the new study of 5,478 consecutive samples evaluated with the Afirma GSC following indeterminate cytopathology results, researchers found that the Afirma GSC identified 64 percent as benign and 36 percent as suspicious for cancer. In comparison, they found that the original Afirma test identified 44 percent of patients as benign following indeterminate cytopathology. Because of the Afirma classifier’s previously demonstrated high negative predictive value (95 percent), patients with benign genomic testing results are typically monitored with imaging in lieu of undergoing diagnostic surgery.
“Our original Afirma test has already transformed thyroid cancer
diagnosis, where we estimate it has helped tens of thousands of patients
avoid unnecessary surgery and saved significant healthcare costs,” said
About Afirma
The Afirma Genomic Sequencing Classifier combines RNA sequencing data
with machine learning to identify patients with benign thyroid nodules
among those with indeterminate cytopathology results in order to
preserve the thyroid. Since the commercial introduction of Afirma in
2011,
About Veracyte
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "expect," "believe," "should," "may,"
"will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that our
genomic tests will transform the diagnosis of thyroid cancer, lung
cancer and idiopathic pulmonary fibrosis; statements regarding our
Afirma Xpression Atlas platform, which we plan to introduce soon; and
Afirma’s ability to significantly improve patient care and reduce
healthcare costs. Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated events
and trends, the economy and other future conditions. Forward-looking
statements involve risks and uncertainties, which could cause actual
results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the benefits of our
tests, the applicability of clinical results to actual outcomes; the
laws and regulations applicable to our business, including potential
regulation by the Food and Drug Administration or other regulatory
bodies; our ability to sell our Afirma tests and successfully transition
to our next-generation Afirma GSC; our ability to successfully achieve
and maintain adoption of and reimbursement for our products; the amount
by which use of our products are able to reduce invasive procedures and
misdiagnosis, and reduce healthcare costs; the occurrence and outcomes
of clinical studies; and other risks set forth in our filings with
the Securities and Exchange Commission, including the risks set forth in
our annual report on Form 10-K for the year ended December 31, 2017, and
our other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180319005409/en/
Source:
Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
or
Investors:
Keith
Kennedy, 650-243-6357
Chief Financial Officer
keith@veracyte.com